|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,71,600.00 KRW | -0.58% |
|
-2.00% | -0.45% |
| 14/07 | Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar | MT |
| 07/07 | Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.85 | 6.99 | 3.16 | 1.5 | 3.35 | |||||
Return on Total Capital | 10.52 | 8.2 | 3.38 | 1.59 | 3.56 | |||||
Return On Equity % | 15.93 | 12.77 | 5.04 | 2.41 | 5.91 | |||||
Return on Common Equity | 16.04 | 13.07 | 5.07 | 2.46 | 5.94 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 57.85 | 45.22 | 48.33 | 47.27 | 59.27 | |||||
SG&A Margin | 9.74 | 8.97 | 9.34 | 21.08 | 22.18 | |||||
EBITDA Margin % | 50.8 | 38.25 | 41.23 | 25.59 | 34.88 | |||||
EBITA Margin % | 47.55 | 35.41 | 38.3 | 23.55 | 32.66 | |||||
EBIT Margin % | 39.59 | 28.34 | 29.93 | 13.83 | 27.98 | |||||
Income From Continuing Operations Margin % | 31.17 | 23.26 | 24.8 | 11.78 | 24.78 | |||||
Net Income Margin % | 30.31 | 23.55 | 24.61 | 11.88 | 24.74 | |||||
Net Avail. For Common Margin % | 30.31 | 23.06 | 24.61 | 11.88 | 24.74 | |||||
Normalized Net Income Margin | 24.47 | 17.22 | 18.77 | 10.45 | 17.29 | |||||
Levered Free Cash Flow Margin | 27.04 | -6.13 | -66.58 | 14.42 | 4.13 | |||||
Unlevered Free Cash Flow Margin | 27.31 | -5.92 | -66.31 | 15.75 | 5.26 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.36 | 0.39 | 0.17 | 0.17 | 0.19 | |||||
Fixed Assets Turnover | 2.02 | 2.33 | 1.96 | 2.89 | 2.82 | |||||
Receivables Turnover (Average Receivables) | 1.62 | 1.68 | 1.7 | 3.3 | 2.77 | |||||
Inventory Turnover (Average Inventory) | 1.67 | 2.1 | 0.61 | 0.65 | 0.61 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.54 | 2.26 | 1.98 | 1.75 | 1.39 | |||||
Quick Ratio | 1.93 | 1.72 | 0.69 | 0.75 | 0.69 | |||||
Operating Cash Flow to Current Liabilities | 0.75 | 0 | 0.22 | 0.28 | 0.15 | |||||
Days Sales Outstanding (Average Receivables) | 224.69 | 217.58 | 214.75 | 110.83 | 131.78 | |||||
Days Outstanding Inventory (Average Inventory) | 217.96 | 174.21 | 593.61 | 566.36 | 599.49 | |||||
Average Days Payable Outstanding | 20.94 | 18.54 | 5.2 | 14.4 | 21.05 | |||||
Cash Conversion Cycle (Average Days) | 421.71 | 373.25 | 803.16 | 662.78 | 710.22 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 18.38 | 18.54 | 11.04 | 12.47 | 21.49 | |||||
Total Debt / Total Capital | 15.52 | 15.64 | 9.94 | 11.09 | 17.69 | |||||
LT Debt/Equity | 4.31 | 3.61 | 0.63 | 0.6 | 2.38 | |||||
Long-Term Debt / Total Capital | 3.64 | 3.05 | 0.56 | 0.53 | 1.96 | |||||
Total Liabilities / Total Assets | 28.62 | 27.45 | 14.02 | 16.5 | 22.31 | |||||
EBIT / Interest Expense | 91.88 | 86.21 | 67.4 | 6.51 | 15.43 | |||||
EBITDA / Interest Expense | 117.87 | 116.36 | 92.83 | 12.04 | 19.24 | |||||
(EBITDA - Capex) / Interest Expense | 110.18 | 101.55 | 71.1 | 10.26 | 17.81 | |||||
Total Debt / EBITDA | 0.77 | 0.91 | 2.11 | 2.41 | 2.57 | |||||
Net Debt / EBITDA | -0.49 | 0.23 | 1.26 | 1.15 | 1.71 | |||||
Total Debt / (EBITDA - Capex) | 0.82 | 1.04 | 2.75 | 2.83 | 2.77 | |||||
Net Debt / (EBITDA - Capex) | -0.52 | 0.26 | 1.65 | 1.35 | 1.85 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 3.38 | 20.63 | -4.71 | 63.45 | 17.01 | |||||
Gross Profit, 1 Yr. Growth % | 7.6 | -5.05 | 1.86 | 59.88 | 46.7 | |||||
EBITDA, 1 Yr. Growth % | 8.8 | -8.84 | 2.71 | 1.45 | 59.52 | |||||
EBITA, 1 Yr. Growth % | 8.9 | -9.76 | 3.04 | 0.5 | 62.27 | |||||
EBIT, 1 Yr. Growth % | 5.32 | -13.03 | 0.65 | -24.47 | 136.69 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 13.33 | -9.3 | 1.57 | -22.39 | 146.25 | |||||
Net Income, 1 Yr. Growth % | 11.92 | -7.18 | -0.41 | -21.09 | 143.58 | |||||
Normalized Net Income, 1 Yr. Growth % | 16.6 | -14.48 | 3.87 | -8.97 | 113.91 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 12.42 | -6.46 | 2.6 | -45.51 | 148.4 | |||||
Accounts Receivable, 1 Yr. Growth % | -12.08 | 47.3 | -42.09 | 29.4 | 47.33 | |||||
Inventory, 1 Yr. Growth % | 50.41 | 6.62 | 393.46 | -8.98 | 1.36 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 0.44 | 5.96 | 20.61 | 2.47 | 36.8 | |||||
Total Assets, 1 Yr. Growth % | 13.03 | 3.83 | 238.06 | 5.5 | 6.08 | |||||
Tangible Book Value, 1 Yr. Growth % | 21.15 | 6.71 | 30.31 | 1.72 | -3.47 | |||||
Common Equity, 1 Yr. Growth % | 18.43 | 5.67 | 310.22 | 2.7 | -1.32 | |||||
Cash From Operations, 1 Yr. Growth % | 159.78 | -99.91 | 62.1T | 67.9 | -28.37 | |||||
Capital Expenditures, 1 Yr. Growth % | -27.16 | 75.4 | 88.94 | -35.7 | -19.87 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -231.34 | -127.5 | 935.48 | -134.39 | -66.52 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -234.25 | -126.31 | 966.93 | -137.71 | -60.92 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 30.15 | 11.14 | 7.21 | 24.8 | 38.29 | |||||
Gross Profit, 2 Yr. CAGR % | 32.12 | 0.24 | -1.66 | 27.61 | 53.15 | |||||
EBITDA, 2 Yr. CAGR % | 34.69 | -1.06 | -3.24 | 2.08 | 27.21 | |||||
EBITA, 2 Yr. CAGR % | 36.64 | -1.56 | -3.57 | 1.76 | 27.71 | |||||
EBIT, 2 Yr. CAGR % | 40.84 | -5.1 | -6.44 | -12.81 | 33.7 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 40.59 | 0.54 | -4.02 | -11.21 | 38.25 | |||||
Net Income, 2 Yr. CAGR % | 38.74 | 1.92 | -3.86 | -11.35 | 38.64 | |||||
Normalized Net Income, 2 Yr. CAGR % | 40.5 | -0.99 | -5.75 | -2.76 | 32.71 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 38.84 | 2.05 | -2.07 | -25.23 | 16.44 | |||||
Accounts Receivable, 2 Yr. CAGR % | 16.28 | 13.8 | -7.64 | -13.44 | 38.07 | |||||
Inventory, 2 Yr. CAGR % | 37.28 | 26.64 | 129.38 | 111.84 | -3.95 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 1.44 | 3.16 | 13.05 | 11.17 | 18.4 | |||||
Total Assets, 2 Yr. CAGR % | 21.25 | 8.33 | 87.36 | 89.04 | 5.79 | |||||
Tangible Book Value, 2 Yr. CAGR % | 15.19 | 13.7 | 17.92 | 15.66 | -0.91 | |||||
Common Equity, 2 Yr. CAGR % | 19.13 | 11.87 | 108.2 | 105.26 | 0.67 | |||||
Cash From Operations, 2 Yr. CAGR % | 38.65 | -95.04 | -23.22 | 3.13T | 9.67 | |||||
Capital Expenditures, 2 Yr. CAGR % | -18.01 | 13.03 | 82.05 | 10.22 | -28.22 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 105.31 | -40.37 | 68.73 | 91.47 | -66.07 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 100.86 | -41.02 | 67.54 | 103.53 | -61.61 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 24.86 | 26.49 | 5.58 | 23.39 | 22.15 | |||||
Gross Profit, 3 Yr. CAGR % | 26.14 | 17.69 | 0.78 | 15.64 | 33.68 | |||||
EBITDA, 3 Yr. CAGR % | 29.46 | 17.74 | 0.18 | -1.7 | 18.46 | |||||
EBITA, 3 Yr. CAGR % | 30.77 | 18.43 | -0.05 | -2.23 | 18.89 | |||||
EBIT, 3 Yr. CAGR % | 32.86 | 19.26 | -3.22 | -12.88 | 21.63 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 35.88 | 20.8 | 0.88 | -10.58 | 24.75 | |||||
Net Income, 3 Yr. CAGR % | 33.1 | 21.34 | 1.14 | -9.98 | 24.17 | |||||
Normalized Net Income, 3 Yr. CAGR % | 33.33 | 18.39 | 0.6 | -6.84 | 22.31 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 32.45 | 21.32 | 2.21 | -19.45 | 11.63 | |||||
Accounts Receivable, 3 Yr. CAGR % | 10.88 | 25.82 | -9.15 | 3.34 | 3.35 | |||||
Inventory, 3 Yr. CAGR % | 52.52 | 26.19 | 99.28 | 68.51 | 65.69 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 2.54 | 2.93 | 8.68 | 9.4 | 19.13 | |||||
Total Assets, 3 Yr. CAGR % | 17.44 | 15.14 | 58.31 | 54.82 | 55.92 | |||||
Tangible Book Value, 3 Yr. CAGR % | 13.54 | 12.29 | 18.99 | 12.59 | 8.89 | |||||
Common Equity, 3 Yr. CAGR % | 16.36 | 14.46 | 72.51 | 64.51 | 60.79 | |||||
Cash From Operations, 3 Yr. CAGR % | 35.68 | -87.79 | 15.27 | -0.34 | 807.81 | |||||
Capital Expenditures, 3 Yr. CAGR % | -7.25 | 5.65 | 34.15 | 28.68 | -0.89 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 61.06 | 4.5 | 54.42 | 0.27 | 7.07 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 57.77 | 1.49 | 54.82 | 2.91 | 17.42 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 23.31 | 19.2 | 17.25 | 25.81 | 17.62 | |||||
Gross Profit, 5 Yr. CAGR % | 23.13 | 8.15 | 13.81 | 21.56 | 19.14 | |||||
EBITDA, 5 Yr. CAGR % | 25.98 | 7.89 | 14.92 | 11.2 | 10.23 | |||||
EBITA, 5 Yr. CAGR % | 28.1 | 7.79 | 15.44 | 11.46 | 10.24 | |||||
EBIT, 5 Yr. CAGR % | 27.9 | 5.32 | 15.08 | 5.22 | 10.14 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 31.87 | 7.06 | 17.84 | 6.8 | 14.43 | |||||
Net Income, 5 Yr. CAGR % | 29.52 | 7.87 | 16.86 | 7.02 | 14.74 | |||||
Normalized Net Income, 5 Yr. CAGR % | 26.8 | 6.1 | 15.66 | 9.43 | 12.39 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 28.55 | 7.19 | 17.15 | -0.05 | 7.68 | |||||
Accounts Receivable, 5 Yr. CAGR % | 7.74 | 14.38 | 3.06 | 8.34 | 7.41 | |||||
Inventory, 5 Yr. CAGR % | 27.59 | 25.31 | 79.57 | 55.25 | 48.8 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 1.83 | 3.59 | 6.62 | 6.15 | 12.47 | |||||
Total Assets, 5 Yr. CAGR % | 14.49 | 12.33 | 41.57 | 40.4 | 34.79 | |||||
Tangible Book Value, 5 Yr. CAGR % | 13.45 | 11.19 | 15.27 | 13.63 | 10.79 | |||||
Common Equity, 5 Yr. CAGR % | 15 | 12.59 | 46.85 | 44.58 | 39.07 | |||||
Cash From Operations, 5 Yr. CAGR % | 31.68 | -71.82 | 8.05 | 13.73 | 12.99 | |||||
Capital Expenditures, 5 Yr. CAGR % | 34.98 | 39.55 | 21.47 | 7.45 | 4.46 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 77.14 | -12.79 | 63.58 | 33.14 | -15.28 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 66.67 | -13.94 | 61.12 | 34.06 | -10.85 |
- Stock Market
- Stocks
- A068270 Stock
- Financials Celltrion, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















